



**Figure 1.** Renal function during cardiopulmonary bypass. GFR: glomerular filtration rate; ERPF: effective renal plasma flow; ECC: extracorporeal circulation; b: hypothermia; n: normothermia; post-op: postoperative.

and aortic valve), the pattern of renal function during CPB, studied with inulin infusion for glomerular filtration rate (GFR) and  $I^{131}$  Hipuran for effective renal plasma flow (ERPF) is well preserved and no differences were found when compared with our own earlier studies in coronary patients [4,5] (Fig. 1). To our knowledge, that was the first such study in valvular surgery patients. GFR and ERPF were well preserved throughout, but ERPF was reduced before surgery. Similar results have been found in others types of surgery [7].

We agree with Landoni and colleagues that the risk for renal dysfunction and acute renal failure depends on many other factors: fasting, hypovolaemia, low cardiac output, emergencies, bleeding and preoperative renal dysfunction. Perioperative factors other than CPB should be considered the main reasons for acute renal failure in patients undergoing coronary and valvular surgery.

G. Lema, W. Merino, C. Salinas  
Department of Anesthesiology  
Pontificia Universidad Católica de Chile  
Santiago, Chile

## References

1. Landoni G, Roberti A, Boroli F *et al.* Mitral valve surgery and acute failure. *Eur J Anesthesiol* 2006; 24: 100–101.
2. Porter GA, Kloster FE, Herr RJ *et al.* Renal complications associated with valve replacement surgery. *J Thorac Cardiovasc Surg* 1967; 53: 145–152.
3. Porter GA, Kloster FE, Herr RJ *et al.* Relationship between alterations in renal hemodynamics during cardiopulmonary bypass and postoperative renal function. *Circulation* 1966; 34: 1005–1021.
4. Lema G, Meneses G, Urzua J *et al.* Effects of extracorporeal circulation on renal function in coronary surgical patients. *Anesth Analg* 1995; 81: 446–451.
5. Lema G, Urzúa J, Jalil R *et al.* Renal protection in patients undergoing cardiopulmonary bypass with preoperative abnormal renal function. *Anesth Analg* 1998; 86: 3–8.
6. Lema G, Canessa R, Carvajal C *et al.* Renal function in valvular and coronary patients undergoing surgery with extracorporeal circulation. Abstract. 29th Annual Meeting & Workshops, Society of Cardiovascular Anesthesiologist, Montreal, Canada, 2007.
7. Colson P, Ribstein J, Seguin JR *et al.* Mechanisms of renal hemodynamic impairment during infrarenal aortic cross-clamping. *Anesth Analg* 1993; 76(2): 458–460.

## Effect of dexmedetomidine on blood pressure and bleeding in maxillo-facial surgery

doi: 10.1017/S0265021507001081

### EDITOR:

We read with great interest the study report by Durmus and colleagues [1] concerning the effect of

dexmedetomidine on bleeding during tympanoplasty or septorhinoplasty. The authors showed that, compared to placebo, dexmedetomidine decreased intraoperative mean arterial pressure (MAP), heart rate (HR) and bleeding in the surgical field.

In a similar prospective study, we have assessed the efficacy of dexmedetomidine in achieving controlled hypotension during maxillofacial surgery [2]. Twenty consecutive ASA I patients undergoing

Correspondence to: Freda Richa, Anesthesia and Intensive Care Department, Hotel-Dieu de France Hospital, Alfred Naccache Street, Ashrafieh, 166830 Beirut, Lebanon. E-mails: fredrich24@yahoo.com and fredrich8@hotmail.com; Tel: +961 3 872077; Fax: +961 1 615295

Accepted for publication 25 May 2007 EJA 4592  
First published online 1 August 2007

Table 1. Haemodynamic values during surgery.

Times	SAP	MAP	HR
Onset DXM	119 ± 16	88 ± 16	75 ± 11
Incision	85 ± 5	64 ± 6	67 ± 9
30 min	87 ± 7	64 ± 7	66 ± 9
60 min	86 ± 9	65 ± 9	65 ± 8
90 min	86 ± 8	64 ± 7	64 ± 8
120 min	83 ± 6	61 ± 6	63 ± 8
Offset DXM	81 ± 5	62 ± 5	63 ± 9

SAP: systolic arterial pressure; MAP: mean arterial pressure;

HR: heart rate; DXM: dexmedetomidine.

Results are expressed as mean ± SD ( $n = 20$ ).

maxillofacial surgery under general anaesthesia received a dexmedetomidine intravenous infusion of  $0.1 \mu\text{g kg}^{-1} \text{min}^{-1}$  for 10 min followed by  $0.4\text{--}0.7 \mu\text{g kg}^{-1} \text{h}^{-1}$ , with the objective of maintaining systolic arterial pressure close to 80 mmHg. Dexmedetomidine infusion was stopped 20 min before the end of surgery. Systolic arterial pressure, MAP and HR were continuously monitored and recorded values were presented in Table 1. Systolic arterial pressure was maintained between 80 and 90 mmHg. Bleeding in the operative field was rated by the surgeons as minimal in 80% of patients and as moderate in 20% of patients. The time interval between end of surgery and tracheal extubation was

$20 \pm 11$  min. Although there was not a control group in our study, our results regarding haemodynamic stability and decreased bleeding with dexmedetomidine in maxillofacial surgery were similar to the results reported by Durmus and colleagues in tympanoplasty and septorhinoplasty.

In summary, our study confirms the conclusion of Durmus and colleagues that dexmedetomidine is efficient in decreasing bleeding when a bloodless surgical field is required. Further controlled studies are needed to compare dexmedetomidine to other hypotensive agents in achieving controlled hypotension during surgery.

F. Richa, A. Yazigi

Department of Anesthesia and Intensive Care

Hotel-Dieu de France Hospital

Saint-Joseph University

Ashrafieh, Beirut, Lebanon

## References

1. Durmus M, But AK, Dogan Z, Yucel A, Miman MC, Ersoy MO. Effect of dexmedetomidine on bleeding during tympanoplasty or septorhinoplasty. *Eur J Anaesthesiol* 2007; 24: 447–453.
2. Richa F, Yazigi A, El Hage C, Gebara S, Hokayem N, Antakly MC. Dexmedetomidine: an agent for controlled hypotension in maxillo-facial surgery. *Eur J Anaesthesiol* 2004; 21(Suppl 32): A242.

## European Journal of Anaesthesiology

### Vacancy for Editor

Vacancies will occur on 1st January 2008 for two Editors of the European Journal of Anaesthesiology. The successful applicants will be a member of the team of 12 Editors, 2 Associate Editors, Editor-in-Chief and Deputy Editor-in-Chief. Duties include dealing with incoming manuscripts allocated by the Editor-in-Chief, liaising with referees and authors and, together with the other members of the Team of Editors, assisting in the smooth running of the journal. Further details can be obtained from the Editor-in-Chief, Professor Brian Pollard, (bjpollard@btinternet.com) to whom expressions of interest and applications should be made.

Editors must be fluent in English and have access to reliable email and internet connections. You must be a member of the ESA or be prepared to join the ESA on appointment.

Applications should be made by letter or email to the Editor-in-Chief accompanied by an up-to-date Curriculum Vitae.

The closing date for receipt of applications is 14th December 2007.